RECURRENT ENDOMETRIAL ENDOMETRIOID ADENOCARCINOMA
Clinical trials for RECURRENT ENDOMETRIAL ENDOMETRIOID ADENOCARCINOMA explained in plain language.
Never miss a new study
Get alerted when new RECURRENT ENDOMETRIAL ENDOMETRIOID ADENOCARCINOMA trials appear
Sign up with your email to follow new studies for RECURRENT ENDOMETRIAL ENDOMETRIOID ADENOCARCINOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug combo trial offers hope for Tough-to-Treat uterine cancer
Disease control OngoingThis study is testing whether adding a drug called ribociclib to a two-drug combination (everolimus and letrozole) works better for women with advanced or returning endometrial cancer. The trial will enroll 90 participants to see if the three-drug combo helps control the cancer l…
Matched conditions: RECURRENT ENDOMETRIAL ENDOMETRIOID ADENOCARCINOMA
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Mar 30, 2026 14:35 UTC
-
Cancer-Killing virus tested in women with advanced uterine cancer
Disease control OngoingThis early-stage trial is testing the safety and best dose of a specially engineered virus designed to infect and kill endometrial cancer cells while sparing healthy ones. The virus can be tracked in the body using imaging. Some participants also receive an oral drug that may hel…
Matched conditions: RECURRENT ENDOMETRIAL ENDOMETRIOID ADENOCARCINOMA
Phase: PHASE1 • Sponsor: Mayo Clinic • Aim: Disease control
Last updated Mar 30, 2026 14:34 UTC
-
New pill tested to fight returning gynecologic cancers
Disease control OngoingThis study is testing an oral medication called tazemetostat for people whose ovarian or endometrial cancer has returned after previous treatments. The drug aims to stop cancer cell growth and shrink tumors. Researchers are enrolling 62 patients to see how well the treatment work…
Matched conditions: RECURRENT ENDOMETRIAL ENDOMETRIOID ADENOCARCINOMA
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Mar 30, 2026 14:31 UTC
-
Major trial tests new weapon against advanced uterine cancer
Disease control OngoingThis large, late-stage study is testing whether adding an immunotherapy drug called pembrolizumab to standard chemotherapy works better for treating advanced or recurrent endometrial cancer. It involves over 800 patients with stage III, IV, or returning cancer. The goal is to see…
Matched conditions: RECURRENT ENDOMETRIAL ENDOMETRIOID ADENOCARCINOMA
Phase: PHASE3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Mar 25, 2026 14:09 UTC
-
New drug combo trial aims to control advanced uterine cancer
Disease control OngoingThis study is testing whether adding a new drug called ipatasertib to a standard hormone therapy (megestrol acetate) is more effective at controlling advanced endometrial cancer than the hormone therapy alone. It involves about 96 women whose cancer has returned or spread. The ma…
Matched conditions: RECURRENT ENDOMETRIAL ENDOMETRIOID ADENOCARCINOMA
Phase: PHASE1, PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Mar 18, 2026 14:41 UTC